{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:35:32Z","timestamp":1793320532810,"version":"4.5.0"},"publisher-location":"New York, NY","reference-count":61,"publisher":"Springer US","isbn-type":[{"value":"9781071637739","type":"print"},{"value":"9781071637746","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-1-0716-3774-6_1","type":"book-chapter","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T10:02:25Z","timestamp":1709287345000},"page":"3-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Blood-Based Biomarkers for Early Alzheimer\u2019s Disease Diagnosis in Real-World Settings"],"prefix":"10.1007","author":[{"given":"Robert","family":"Perneczky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Laske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Grimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emrah","family":"D\u00fczel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the German Network Memory Clinics \u2013 Diagnostic Tools Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"1_CR1","volume-title":"World Alzheimer report \u2013 the global impact of dementia","author":"M Prince","year":"2015","unstructured":"Prince M et al (2015) World Alzheimer report \u2013 the global impact of dementia"},{"key":"1_CR2","unstructured":"WHO (2017) Global action plan on the public health response to dementia 2017\u20132025"},{"key":"1_CR3","unstructured":"Nationale Demenzstrategie (2020)"},{"issue":"3","key":"1_CR4","first-page":"2","volume":"8","author":"JP Hlavka","year":"2019","unstructured":"Hlavka JP, Mattke S, Liu JL (2019) Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer\u2019s treatment. Rand Health Q 8(3):2","journal-title":"Rand Health Q"},{"issue":"3","key":"1_CR5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jalz.2016.09.008","volume":"13","author":"AH Simonsen","year":"2017","unstructured":"Simonsen AH et al (2017) Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement 13(3):274\u2013284","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1_CR6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12916-019-1283-z","volume":"17","author":"R Perneczky","year":"2019","unstructured":"Perneczky R et al (2019) Translational research on reserve against neurodegenerative disease: consensus report of the international conference on cognitive reserve in the Dementias and the Alzheimer\u2019s Association reserve, resilience and protective factors professional interest area working groups. BMC Med 17(1):47","journal-title":"BMC Med"},{"issue":"3","key":"1_CR7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/ageing\/afj054","volume":"35","author":"R Perneczky","year":"2006","unstructured":"Perneczky R et al (2006) Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. Age Ageing 35(3):240\u2013245","journal-title":"Age Ageing"},{"issue":"2","key":"1_CR8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/gps.1444","volume":"21","author":"R Perneczky","year":"2006","unstructured":"Perneczky R et al (2006) Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome. Int J Geriatr Psychiatry 21(2):158\u2013162","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"1_CR9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","volume":"19","author":"F Jessen","year":"2020","unstructured":"Jessen F et al (2020) The characterisation of subjective cognitive decline. Lancet Neurol 19(3):271\u2013278","journal-title":"Lancet Neurol"},{"key":"1_CR10","unstructured":"Jessen F et al (2022) Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimers Dement"},{"issue":"3","key":"1_CR11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3233\/JAD-180196","volume":"64","author":"U Strohmaier","year":"2018","unstructured":"Strohmaier U et al (2018) Patients with dementia in primary care: who is referred to a neurologist\/psychiatrist and what patient-oriented factors are associated with the visit? J Alzheimers Dis 64(3):925\u2013932","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1_CR12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.dadm.2014.11.007","volume":"1","author":"T Eichler","year":"2015","unstructured":"Eichler T et al (2015) Rates of formal diagnosis of dementia in primary care: the effect of screening. Alzheimers Dement (Amst) 1(1):87\u201393","journal-title":"Alzheimers Dement (Amst)"},{"issue":"2","key":"1_CR13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/ageing\/afu205","volume":"44","author":"S Bell","year":"2015","unstructured":"Bell S et al (2015) A diagnosis for pound55: what is the cost of government initiatives in dementia case finding. Age Ageing 44(2):344\u2013345","journal-title":"Age Ageing"},{"issue":"19","key":"1_CR14","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1055\/a-0651-1978","volume":"143","author":"J Wangler","year":"2018","unstructured":"Wangler J, Fellgiebel A, Jansky M (2018) Dementia diagnosis in general practitioner care - attitudes, procedures and challenges from the perspective of general practitioners in Rhineland-Palatinate. Dtsch Med Wochenschr 143(19):e165\u2013e171","journal-title":"Dtsch Med Wochenschr"},{"issue":"1","key":"1_CR15","doi-asserted-by":"crossref","first-page":"e12130","DOI":"10.1002\/dad2.12130","volume":"13","author":"L Sannemann","year":"2021","unstructured":"Sannemann L et al (2021) General practitioners\u2019 attitude toward early and pre-dementia diagnosis of AD in five European countries-a MOPEAD project survey. Alzheimers Dement (Amst) 13(1):e12130","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"1_CR16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1176\/appi.neuropsych.13060145","volume":"26","author":"DW Scharre","year":"2014","unstructured":"Scharre DW et al (2014) Community cognitive screening using the self-administered gerocognitive examination (SAGE). J Neuropsychiatry Clin Neurosci 26(4):369\u2013375","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"8","key":"1_CR17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.22258","volume":"323","author":"CD Patnode","year":"2020","unstructured":"Patnode CD et al (2020) Screening for cognitive impairment in older adults: updated evidence report and systematic review for the US preventive services task force. JAMA 323(8):764\u2013785","journal-title":"JAMA"},{"issue":"2","key":"1_CR18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JAD-132027","volume":"41","author":"L Rami","year":"2014","unstructured":"Rami L et al (2014) The subjective cognitive decline questionnaire (SCD-Q): a validation study. J Alzheimers Dis 41(2):453\u2013466","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1_CR19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189\u2013198","journal-title":"J Psychiatr Res"},{"issue":"4","key":"1_CR20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695\u2013699","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1_CR21","doi-asserted-by":"crossref","first-page":"e12217","DOI":"10.1002\/dad2.12217","volume":"13","author":"F Ohman","year":"2021","unstructured":"Ohman F et al (2021) Current advances in digital cognitive assessment for preclinical Alzheimer\u2019s disease. Alzheimers Dement (Amst) 13(1):e12217","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"1_CR22","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","volume":"12","author":"NC Cullen","year":"2021","unstructured":"Cullen NC et al (2021) Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun 12(1):3555","journal-title":"Nat Commun"},{"issue":"1","key":"1_CR23","doi-asserted-by":"crossref","first-page":"e12242","DOI":"10.1002\/dad2.12242","volume":"13","author":"J Pannee","year":"2021","unstructured":"Pannee J et al (2021) The global Alzheimer\u2019s Association round robin study on plasma amyloid beta methods. Alzheimers Dement (Amst) 13(1):e12242","journal-title":"Alzheimers Dement (Amst)"},{"key":"1_CR24","doi-asserted-by":"crossref","unstructured":"Mattke S, Hanson M (2021) Expected wait times for access to a disease-modifying Alzheimer\u2019s treatment in the United States. Alzheimers Dement","DOI":"10.1002\/alz.12470"},{"issue":"6","key":"1_CR25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S et al (2021) Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 27(6):1034\u20131042","journal-title":"Nat Med"},{"issue":"8","key":"1_CR26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","volume":"17","author":"A Yilmaz","year":"2017","unstructured":"Yilmaz A et al (2017) Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn 17(8):761\u2013770","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"1_CR27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","volume":"11","author":"M Khalil","year":"2020","unstructured":"Khalil M et al (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 11(1):812","journal-title":"Nat Commun"},{"issue":"2","key":"1_CR28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s43587-021-00028-4","volume":"1","author":"SA Kaeser","year":"2021","unstructured":"Kaeser SA et al (2021) A neuronal blood marker is associated with mortality in old age. Nat Aging 1(2):218\u2013225","journal-title":"Nat Aging"},{"issue":"4","key":"1_CR29","doi-asserted-by":"crossref","first-page":"fcac174","DOI":"10.1093\/braincomms\/fcac174","volume":"4","author":"J Simren","year":"2022","unstructured":"Simren J et al (2022) Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5\u201390 years. Brain Commun 4(4):fcac174","journal-title":"Brain Commun"},{"issue":"2","key":"1_CR30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40520-021-02054-z","volume":"34","author":"A Ladang","year":"2022","unstructured":"Ladang A et al (2022) Neurofilament light chain concentration in an aging population. Aging Clin Exp Res 34(2):331\u2013339","journal-title":"Aging Clin Exp Res"},{"issue":"9","key":"1_CR31","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 76(9):1035\u20131048","journal-title":"JAMA Neurol"},{"issue":"6","key":"1_CR32","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/alz.12466","volume":"18","author":"JA Syrjanen","year":"2022","unstructured":"Syrjanen JA et al (2022) Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement 18(6):1128\u20131140","journal-title":"Alzheimers Dement"},{"key":"1_CR33","doi-asserted-by":"crossref","unstructured":"O\u2019Bryant SE et al (2022) Medical comorbidities and ethnicity impact plasma Alzheimer\u2019s disease biomarkers: important considerations for clinical trials and practice. Alzheimers Dement","DOI":"10.1002\/alz.12647"},{"key":"1_CR34","doi-asserted-by":"crossref","unstructured":"Huber H et al (2023) Levels of Alzheimer\u2019s disease blood biomarkers are altered after food intake-a pilot intervention study in healthy adults. Alzheimers Dement","DOI":"10.1002\/alz.13163"},{"issue":"1","key":"1_CR35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13195-022-01011-w","volume":"14","author":"PR Kac","year":"2022","unstructured":"Kac PR et al (2022) Diagnostic value of serum versus plasma phospho-tau for Alzheimer\u2019s disease. Alzheimers Res Ther 14(1):65","journal-title":"Alzheimers Res Ther"},{"key":"1_CR36","doi-asserted-by":"crossref","first-page":"894119","DOI":"10.3389\/fneur.2022.894119","volume":"13","author":"N Rubsamen","year":"2022","unstructured":"Rubsamen N et al (2022) A method to combine neurofilament light measurements from blood serum and plasma in clinical and population-based studies. Front Neurol 13:894119","journal-title":"Front Neurol"},{"issue":"2","key":"1_CR37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O et al (2019) Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med 25(2):277\u2013283","journal-title":"Nat Med"},{"issue":"10","key":"1_CR38","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1038\/s41380-020-0838-x","volume":"26","author":"A O\u2019Connor","year":"2021","unstructured":"O\u2019Connor A et al (2021) Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer\u2019s disease: a longitudinal cohort study. Mol Psychiatry 26(10):5967\u20135976","journal-title":"Mol Psychiatry"},{"key":"1_CR39","doi-asserted-by":"crossref","unstructured":"O\u2019Connor A et al (2022) Plasma GFAP in presymptomatic and symptomatic familial Alzheimer\u2019s disease: a longitudinal cohort study. J Neurol Neurosurg Psychiatry","DOI":"10.1136\/jnnp-2022-329663"},{"issue":"9","key":"1_CR40","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/brain\/awab163","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB et al (2021) Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain 144(9):2826\u20132836","journal-title":"Brain"},{"issue":"3","key":"1_CR41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S et al (2020) Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26(3):379\u2013386","journal-title":"Nat Med"},{"issue":"7","key":"1_CR42","first-page":"e688","volume":"98","author":"Y Li","year":"2022","unstructured":"Li Y et al (2022) Validation of plasma amyloid-beta 42\/40 for detecting Alzheimer disease amyloid plaques. Neurology 98(7):e688\u2013e699","journal-title":"Neurology"},{"key":"1_CR43","doi-asserted-by":"crossref","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, Rodr\u00edguez-Baz P, Carmona-Iragui M, Barroeta I, Ill\u00e1n-Gala I, Santos-Santos M, Fortea J, Lle\u00f3 A, Tondo M, Alcolea D (2023) Diagnostic performance of plasma A\u03b21-42, A\u03b21-40 and pTau181 in the LUMIPULSE automated platform for the detection of Alzheimer disease. medRxiv","DOI":"10.1101\/2023.04.20.23288852"},{"issue":"1","key":"1_CR44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13195-022-01116-2","volume":"14","author":"EN Wilson","year":"2022","unstructured":"Wilson EN et al (2022) Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer\u2019s disease. Alzheimers Res Ther 14(1):172","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"1_CR45","doi-asserted-by":"crossref","first-page":"e28263","DOI":"10.1371\/journal.pone.0028263","volume":"6","author":"H Zetterberg","year":"2011","unstructured":"Zetterberg H et al (2011) Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans. PLoS One 6(12):e28263","journal-title":"PLoS One"},{"issue":"1","key":"1_CR46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41467-019-13901-z","volume":"11","author":"K Kim","year":"2020","unstructured":"Kim K et al (2020) Clinically accurate diagnosis of Alzheimer\u2019s disease via multiplexed sensing of core biomarkers in human plasma. Nat Commun 11(1):119","journal-title":"Nat Commun"},{"issue":"2","key":"1_CR47","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari TK et al (2021) Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol Psychiatry 26(2):429\u2013442","journal-title":"Mol Psychiatry"},{"issue":"3","key":"1_CR48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez J et al (2020) Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol 140(3):267\u2013278","journal-title":"Acta Neuropathol"},{"issue":"9","key":"1_CR49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH et al (2021) Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 20(9):739\u2013752","journal-title":"Lancet Neurol"},{"key":"1_CR50","unstructured":"Chatterjee P et al (2021) Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease. Alzheimers Dement"},{"issue":"3","key":"1_CR51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH et al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med 26(3):387\u2013397","journal-title":"Nat Med"},{"issue":"4","key":"1_CR52","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","volume":"78","author":"A Moscoso","year":"2021","unstructured":"Moscoso A et al (2021) Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol 78(4):396\u2013406","journal-title":"JAMA Neurol"},{"issue":"8","key":"1_CR53","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S et al (2020) Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324(8):772\u2013781","journal-title":"JAMA"},{"issue":"1","key":"1_CR54","doi-asserted-by":"crossref","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A et al (2022) Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med 14(1):e14408","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1_CR55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C et al (2021) Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther 13(1):68","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1_CR56","doi-asserted-by":"crossref","first-page":"e000143","DOI":"10.1136\/bmjno-2021-000143","volume":"3","author":"J Alagaratnam","year":"2021","unstructured":"Alagaratnam J et al (2021) Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. BMJ Neurol Open 3(1):e000143","journal-title":"BMJ Neurol Open"},{"issue":"1","key":"1_CR57","first-page":"e12099","volume":"12","author":"LL Raket","year":"2020","unstructured":"Raket LL et al (2020) Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer\u2019s disease. Alzheimers Dement (Amst) 12(1):e12099","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"1_CR58","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","volume":"92","author":"D Alcolea","year":"2021","unstructured":"Alcolea D et al (2021) Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. J Neurol Neurosurg Psychiatry 92(11):1206\u20131214","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7691","key":"1_CR59","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A et al (2018) High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature 554(7691):249\u2013254","journal-title":"Nature"},{"issue":"4","key":"1_CR60","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/alz.12790","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P et al (2023) Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. Alzheimers Dement 19(4):1358\u20131371","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1_CR61","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/brain\/awad005","volume":"146","author":"R Perneczky","year":"2023","unstructured":"Perneczky R et al (2023) Anti-amyloid antibody therapies in Alzheimer\u2019s disease. Brain 146(3):842\u2013849","journal-title":"Brain"}],"container-title":["Methods in Molecular Biology","Biomarkers for Alzheimer\u2019s Disease Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3774-6_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T12:02:20Z","timestamp":1716465740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3774-6_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9781071637739","9781071637746"],"references-count":61,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3774-6_1","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"2 March 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}